{"id":300258,"date":"2025-10-13T15:40:20","date_gmt":"2025-10-13T15:40:20","guid":{"rendered":"https:\/\/www.europesays.com\/us\/300258\/"},"modified":"2025-10-13T15:40:20","modified_gmt":"2025-10-13T15:40:20","slug":"active-pharmaceutical-ingredients-cdmo-market-size-expected-to-hit-usd-273-92-bn-by-2034","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/300258\/","title":{"rendered":"Active Pharmaceutical Ingredients CDMO Market Size Expected to Hit USD 273.92 Bn by 2034"},"content":{"rendered":"

<\/p>\n

According to Nova One Advisor, the global active
\npharmaceutical ingredients CDMO market<\/b><\/a> <\/b>size is expected to be
\nworth around 273.92 billion by 2034, increasing from USD 139.33 billion in 2025,
\nrepresenting a healthy CAGR of 7.8% from 2025 to 2034.<\/p>\n

<\/p>\n

The active pharmaceutical ingredients CDMO<\/b><\/a>
\nmarket is expanding as partnering with CDMOs by pharmaceutical organizations increases
\ntheir ability to solve some of the most persistent challenges faced by drug
\nmanufacturers. This partnership enables a drug developer to avoid the massive
\ncapital expenditure needed to equip, build, and staff its own cGMP-compliant
\nmanufacturing services.<\/p>\n

\u2022 A CDMO offers enthusiastic subject matter
\nexperts during the development and manufacturing process who have a wealth of
\nexperience, knowledge, and can tackle probable challenges.<\/p>\n

The Complete Study is Now Available for
\nImmediate Access | Download the Sample Pages of this Report@\u00a0 <\/b>https:\/\/www.novaoneadvisor.com\/report\/sample\/8371<\/b><\/a>
\n<\/b><\/p>\n

Active Pharmaceutical Ingredients CDMO
\nMarket Highlights:<\/b><\/p>\n

\ud83d\udd39<\/b>Asia Pacific dominated the overall Active Pharmaceutical Ingredients
\nCDMO market with a revenue share of 39% in 2024.<\/p>\n

\ud83d\udd39<\/b>The U.S. accounted for a dominant revenue share in the API CDMO
\nmarket in North America in 2024.<\/p>\n

\ud83d\udd39<\/b>The traditional active pharmaceutical ingredients segment held the
\nlargest share of 40% in 2024.<\/p>\n

\ud83d\udd39<\/b>The antibody-drug conjugate segment is expected to show lucrative
\ngrowth during the forecast period.<\/p>\n

\ud83d\udd39<\/b>The synthetic segment dominated the API CDMO market and accounted
\nfor the largest revenue share of 74% in 2024.<\/p>\n

\ud83d\udd39<\/b>The biotech segment is estimated to register a faster CAGR over the
\nforecast period.<\/p>\n

\ud83d\udd39<\/b>The innovative drugs segment dominated the API CDMO market and
\naccounted for the largest revenue share of 74% in 2024.<\/p>\n

\ud83d\udd39<\/b>The generic segment is expected to showcase lucrative growth over
\nthe forecast period.<\/p>\n

\ud83d\udd39<\/b>The oncology segment dominated the active pharmaceutical ingredients
\nCDMO market and accounted for the largest revenue share of 36% in 2024.<\/p>\n

\ud83d\udd39<\/b>The glaucoma segment is expected to experience lucrative growth over
\nthe forecast period.<\/p>\n

\ud83d\udd39<\/b>The commercial segment held a dominant market share of 91% in 2024.<\/p>\n

\ud83d\udd39<\/b>The clinical segment is expected to showcase lucrative growth over
\nthe forecast period.<\/p>\n

Market Overview and Industry Potential<\/b><\/p>\n

CDMOs provide a wide range of solutions in
\nthe pharmaceutical<\/b><\/a>
\ndevelopment and manufacturing techniques, including drug substance such as
\nactive ingredients manufacturing, drug product manufacturing, analytical
\ntesting<\/b><\/a> and quality control techniques, process development and
\noptimisation, technology transfer, scale-up from clinical to commercial
\nmanufacturing, government compliance support, and packaging and distribution.
\nIt also provides a combination of both research and manufacturing solutions.<\/p>\n

\u2b25\ufe0e <\/b>For Instance, In April 2025, Sun
\nNuclear, a Mirion Medical company, announced the acquisition of Oncospace, a
\ncompany offering cloud-based, AI-driven solutions for the radiation oncology
\ncommunity. This strategic move underscores the Sun Nuclear commitment to
\nleveraging cutting-edge technology to improve treatment outcomes on behalf of
\ncustomers.<\/p>\n

Recently, CDMOs have adopted sustainable
\npractices such as using single-use
\nbioreactors<\/b><\/a>, continuous flow manufacturing, and biocatalysis to cut
\nwaste and boost efficiency. Those that actively incorporate sustainability into
\ntheir corporate strategy are more likely to attract customers and build lasting
\npartnerships. The main advantage of this technology is its ability to lower
\nenergy use, thanks to more efficient heat and mass transfer. As a result, drug API<\/b><\/a>
\ncompanies are increasingly choosing CDMOs committed to environmentally friendly
\noperations.<\/p>\n

Latest Trends of the Market<\/b><\/p>\n

\u2b25\ufe0e <\/b>In July 2025, Phlow Corp., a leading American pharmaceutical
\ncontract development and manufacturing organization (CDMO<\/b><\/a>),
\nand Antheia, the pharmaceutical ingredients manufacturer transforming essential
\nmedicine supply chains, announced an ongoing partnership to onshore production
\nof essential medicines and establish more efficient, agile, and resilient
\npharmaceutical supply chains in the United States.<\/p>\n

\u2b25\ufe0e <\/b>In February 2025, SK Pharmteco Cell
\n& Gene Europe<\/b><\/a>, a global contract development, manufacturing, and
\nanalytical testing organization serving the pharmaceutical and cell & gene
\ntherapy industries, along with Assistance Publique and Institut Imagine,
\nannounced the signing of a contract for the production of a 200L CGMP clinical
\nbatch of lentiviral
\nvector<\/b><\/a> (LVV) and associated regulatory support.<\/p>\n

Recently Advanced One-Stop-Shop Solution
\nProvided by the CDMO: Market\u2019s Largest Potential<\/b><\/p>\n

Integrated CDMOs offer a comprehensive
\none-stop-shop strategy, covering everything from cell line development and
\nprocess characterization to commercial manufacturing and regulatory filing
\nsupport. This approach reduces delays caused by tech transfers between vendors.
\nSuch end-to-end services and one-stop shop contract organizations remain
\nappealing to drug sponsors looking for speed, scalability, and strong consumer
\nsupport. They streamline the whole process, from early discovery and
\ndevelopment to commercial manufacturing and distribution, driving the growth in
\nthe active
\npharmaceutical ingredients CDMO<\/b><\/a> market.<\/p>\n

Active Pharmaceutical Ingredients CDMO
\nMarket Report Scope<\/b><\/p>\n\n\n

Report Attribute<\/b><\/p>\n<\/td>\n\n

Details<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Market Size in
\n 2025<\/b><\/p>\n<\/td>\n\n

USD 139.33 Billion<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Market Size by
\n 2034<\/b><\/p>\n<\/td>\n\n

USD 273.92 Billion<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Growth Rate From
\n 2025 to 2034<\/b><\/p>\n<\/td>\n\n

CAGR of 7.8%<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Base Year<\/b><\/p>\n<\/td>\n\n

2024<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Forecast Period<\/b><\/p>\n<\/td>\n\n

2025 to 2034<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Segments Covered<\/p>\n<\/td>\n\n

Product, Synthesis,
\n Drug, Application, Workflow, Region<\/p>\n<\/td>\n<\/tr>\n\n\n

Market Analysis
\n (Terms Used)<\/p>\n<\/td>\n\n

Value (US$
\n Million\/Billion) or (Volume\/Units)<\/p>\n<\/td>\n<\/tr>\n\n\n

Report Coverage<\/p>\n<\/td>\n\n

Revenue forecast,
\n company ranking, competitive landscape, growth factors, and trends<\/p>\n<\/td>\n<\/tr>\n

\u00a0<\/p>\n

Buy Now Full Report:<\/b> https:\/\/www.novaoneadvisor.com\/report\/checkout\/8371<\/b><\/a>\n<\/p>\n

Asia Pacific Active Pharmaceutical
\nIngredients CDMO Market Size and Trends 2025 to 2034<\/b><\/p>\n

The Asia Pacific active pharmaceutical
\ningredients CDMO market size was valued at USD 51.35 billion in 2024 and is
\nprojected to surpass around USD 107.82 billion by 2034, registering a CAGR of
\n7.7% over the forecast period of 2025 to 2034.<\/p>\n

<\/p>\n

North America dominated the active
\npharmaceutical ingredients CDMO market in 2024, due to its advanced
\nmanufacturing solutions, such as advancing complex, high-value APIs, including
\nHPAPIs and biologics. CDMOs in North America have developed techniques to
\nhandle these substances safely and effectively. Also, the presence of a strong
\ngovernment environment and high R&D spending drives the growth of the
\nmarket.<\/p>\n

<\/p>\n

\u2b25\ufe0e <\/b>For Instance, In July 2025, ESTEVE
\nacquires Regis Technologies, a United States-based Contract Development and
\nManufacturing Organization (CDMO<\/b><\/a>),
\nheadquartered in Chicago. This strategic move allows ESTEVE CDMO a physical
\npresence in the United States, expanding its contract development and
\nmanufacturing solutions for innovative small-molecule active
\npharmaceutical ingredients<\/b><\/a> (APIs) across the entire drug development
\nlifecycle<\/p>\n

The U.S. has a high presence of pharmaceutical
\nand biotechnology organizations<\/b><\/a> and is increasing for adoption of novel
\nmanufacturing processes. This drives consistent demand for CDMO solutions to
\nhelp a strong pipeline of new and complex drug molecules.<\/p>\n

Why is Asia Pacific the Fastest Growing
\nin the Active Pharmaceutical Ingredients CDMO Market?<\/b><\/p>\n

APAC is the fastest-growing region in the
\nmarket, with lower healthcare manufacturing expenses, the presence of a huge,
\nskilled workforce, strong government spending and policies in major countries
\nsuch as China and India, a massive API production infrastructure, and growing
\nworldwide demand for generic and affordable medicine solutions, which drives
\nthe growth of the market.<\/p>\n

Buy Now Full Report:<\/b> https:\/\/www.novaoneadvisor.com\/report\/checkout\/8371<\/b><\/a>\n<\/p>\n

Active Pharmaceutical Ingredients CDMO
\nMarket Segmentation Analysis:<\/b><\/p>\n

By Type Analysis:<\/b><\/p>\n

The synthetic
\nAPIs<\/b><\/a> segment dominates in the active pharmaceutical ingredients CDMO
\nMarket, as manufacturing of synthetic APIs is usually more cost-efficient. They
\nprovide advantages from low-cost raw materials, effective scaling, and
\nstreamlined manufacturing processes, making drugs such as aspirin and
\nparacetamol highly affordable. Synthetic APIs rely on chemical inputs that are
\nbroadly available, constant in price, and effortlessly sourced from worldwide
\nsuppliers. Raw
\nmaterials<\/b><\/a> for synthetic drugs are generally shipped to centralized facilities,
\nand the end products often remain stable at room temperature, making both
\nstorage and transportation simpler.<\/p>\n

On the other hand, the biotech
\nAPIs<\/b><\/a> segment is expected to grow significantly during the forecast
\nperiod, as biotech API manufacturing involves single-use
\nbioreactors<\/b><\/a>; these systems are composed of plastic material, which is
\nsealed and sterilized by gamma radiation. Single-use bioreactors significant
\ndevice in the production of biotech API and HPAPI<\/b><\/a>.
\nIt is advantageous for both downstream and upstream processes. They allow the
\ndevelopment of targeted and biologic medicines, like vaccines and antibody
\ntherapies.<\/p>\n

By Drug Insights Analysis:<\/b><\/p>\n

The generic APIs<\/b><\/a>
\nsegment dominated the market in 2024, as it makes medical care more affordable
\nand accessible. Generic APIs contribute to healthier communities and stronger
\neconomies. Simple to enhance when application functionality is added, and there
\nis one single place to make modifications and publish novel API contracts.\u00a0
\nGeneric API is \u0430 one-size-fits-all, trying hard to accommodate the requirements
\nof each customer. <\/p>\n

On the other hand, the innovative drugs
\nsegment is expected to grow at the fastest CAGR in the market during the
\nforecast period, as APIs are the backbone of innovative medicine manufacturing,
\nforming significant components in drug formulations that manage, treat, and prevent
\ndiseases. <\/p>\n

By Application Analysis:<\/b><\/p>\n

The Oncology segment<\/b><\/a>
\ndominated the market in 2024, as high-potency active pharmaceutical ingredients
\n(HPAPIs) are considered significant in the production of oncology drugs<\/b><\/a>,
\nenabling the production of personalized
\ncancer therapies<\/b><\/a>. These API deliver efficient treatment at minimum
\ndoses, making them important for reducing adverse effects while maximizing
\ntherapeutic effect. This quality has caused a significant increase in the
\ndemand for HPAPI manufacturing in oncology.<\/p>\n

On the other hand, the cardiovascular
\ndisease<\/b><\/a> and diabetes APIs segment is expected to grow at the fastest
\nCAGR in the market during the forecast period, as API play an important role in
\ncardiology and diabetology drug manufacturing. Glimepiride, Glipizide,
\nIndapamide, and Atorvastatin have been discovered to have their unique
\ncontributions to treating diabetes and heart disease. These APIs provide
\ntargeted action with variable durations of control. Its longer effect ensures
\nsustained cholesterol control, lowering the challenges of plaque buildup in
\narteries and defensive the heart from possible damage. <\/p>\n

By Workflow Analysis:<\/b><\/p>\n

The commercial<\/b><\/a>
\nmanufacturing segment dominated the market in 2024, as this segment has a
\nlarge-scale production strength of active pharmaceutical ingredients. It is
\nsignificant to offer consistent, quality, and compliant products available for
\ncommercial distribution. It offers advantages like reduction of cost through
\neconomies of scale and well-organized processes, access to advanced technology,
\nand faster time-to-market through rationalized production.<\/p>\n

<\/p>\n

On the other hand, the clinical development
\nmanufacturing segment is expected to grow at the fastest CAGR in the market
\nduring the forecast period, as it offers significant benefits for
\npharmaceutical organizations, particularly during the critical initial stages
\nof drug development.<\/p>\n

Active Pharmaceutical Ingredients CDMO
\nMarket Companies:<\/b><\/p>\n

\u2022 Cambrex
\nCorporation<\/b><\/a><\/p>\n

\u2022 Recipharm AB<\/p>\n

\u2022 Thermo Fisher Scientific
\nInc<\/b><\/a>. (Pantheon)<\/p>\n

\u2022 CordenPharma International<\/p>\n

\u2022 Samsung
\nBiologics<\/b><\/a><\/p>\n

\u2022 Lonza<\/b><\/a><\/p>\n

\u2022 Catalent,
\nInc.<\/b><\/a><\/p>\n

\u2022 Siegfried
\nHolding AG<\/b><\/a><\/p>\n

\u2022 Piramal Pharma Solutions<\/b><\/a><\/p>\n

\u2022 Boehringer Ingelheim International GmbH<\/p>\n

What is Going Around the Globe?<\/b><\/p>\n

\u2b25\ufe0e <\/b>In April 2025, Sumitomo Chemical
\nestablished a new company, Sumitomo Chemical Advanced Medical Solutions America
\nLLC, in Marlborough, Massachusetts, the United States. This company will serve
\nas a CRO for Sumitomo Chemical\u2019s Oligonucleotide CDMO business.<\/p>\n

\u2b25\ufe0e <\/b>In May 2025, Lonza<\/b><\/a>, a contract development and
\nmanufacturing organisation (CDMO), announced the launch of its new
\nDesign2Optimize platform to enhance process development and manufacturing of
\nsmall molecule APIs.<\/p>\n

\u2b25\ufe0e <\/b>In October 2024, Thermo Fisher Scientific<\/b><\/a>
\nlaunched Accelerator Drug Development, described as the company\u2019s 360\u00b0 contract
\ndevelopment and manufacturing organization and contract research organization
\ndrug development solutions, as part of its showcase at CPHI Milan.<\/p>\n

You can place an order or ask any
\nquestions, please feel free to contact at\u00a0<\/b>sales@novaoneadvisor.com<\/b><\/a> \u00a0|
\n+1 804 441 9344<\/b><\/p>\n

Related Report \u2013 <\/b><\/p>\n

\ud83d\udd39Biopharmaceutical CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/biopharmaceutical-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39Biologics CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/biologics-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39Oligonucleotide CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/oligonucleotide-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39Cell And Gene Therapy CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/cell-and-gene-therapy-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39U.S. Active Pharmaceutical Ingredients CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/us-active-pharmaceutical-ingredients-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39North America Topical Drugs CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/north-america-topical-drugs-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39Topical Drugs CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/topical-drugs-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39U.S. Pharmaceutical CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/us-pharmaceutical-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

\ud83d\udd39Pharmaceutical CDMO Market- <\/b>https:\/\/www.novaoneadvisor.com\/report\/pharmaceutical-cdmo-market<\/b><\/a>
\n<\/b><\/p>\n

Active Pharmaceutical Ingredients CDMO
\nMarket Report Segmentation<\/b><\/p>\n

This report forecasts revenue growth at
\ncountry levels and provides an analysis of the latest industry trends in each of
\nthe sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has
\nsegmented the Active Pharmaceutical Ingredients CDMO market.<\/p>\n

By Product<\/b><\/p>\n

\u2022 Traditional Active Pharmaceutical
\nIngredients (Traditional API)<\/p>\n

\u2022 Highly Potent Active Pharmaceutical
\nIngredients (HP-API)<\/p>\n

\u2022 Antibody Drug Conjugate (ADC)<\/p>\n

\u2022 Others<\/p>\n

By Synthesis<\/b><\/p>\n

\u2022 Synthetic<\/p>\n

\u2022 Biotech<\/p>\n

By Drug <\/b><\/p>\n

\u2022 Innovative<\/p>\n

\u2022 Generics<\/p>\n

By Workflow <\/b><\/p>\n

\u2022 Clinical<\/p>\n

\u2022 Commercial<\/p>\n

By Application <\/b><\/p>\n

\u2022 Oncology<\/p>\n

\u2022 Hormonal<\/p>\n

\u2022 Glaucoma<\/p>\n

\u2022 Cardiovascular disease<\/p>\n

\u2022 Diabetes<\/p>\n

\u2022 Others<\/p>\n

By Region<\/b><\/p>\n

\u2022 North America<\/p>\n

\u2022 Europe<\/p>\n

\u2022 Asia-Pacific<\/p>\n

\u2022 Latin America<\/p>\n

\u2022 Middle East & Africa (MEA)<\/p>\n

Immediate Delivery Available | Buy This
\nPremium Research <\/b>https:\/\/www.novaoneadvisor.com\/report\/checkout\/8371<\/b><\/a>
\n<\/b><\/p>\n

About-Us<\/b><\/p>\n

Nova One Advisor is a global leader
\nin market intelligence and strategic consulting, committed to delivering deep,
\ndata-driven insights that power innovation and transformation across
\nindustries. With a sharp focus on the evolving landscape of life sciences, we
\nspecialize in navigating the complexities of cell and gene therapy, drug
\ndevelopment, and the oncology market, enabling our clients to lead in some of
\nthe most revolutionary and high-impact areas of healthcare.<\/p>\n

Our expertise spans the entire
\nbiotech and pharmaceutical value chain, empowering startups, global
\nenterprises, investors, and research institutions that are pioneering the next
\ngeneration of therapies in regenerative medicine, oncology, and precision
\nmedicine. <\/p>\n

Web: <\/b>https:\/\/www.novaoneadvisor.com\/<\/b><\/a><\/p>\n

Contact Us<\/b><\/p>\n

USA:<\/b>\u00a0+1 804 420 9370<\/p>\n

Email: <\/b>sales@novaoneadvisor.com<\/b><\/a><\/p>\n

For Latest Update Follow Us: <\/b>LinkedIn<\/b><\/a> <\/b><\/p>\n","protected":false},"excerpt":{"rendered":"According to Nova One Advisor, the global active pharmaceutical ingredients CDMO market size is expected to be worth…\n","protected":false},"author":3,"featured_media":300259,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,135,67,132,68],"class_list":{"0":"post-300258","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-markets","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115367616510563470","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/300258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=300258"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/300258\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/300259"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=300258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=300258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=300258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}